Citations

Clear

3057 citation(s) found for "Cd, Johnson".

Racial and Ethnic and Sex Disparities in the Outcomes and Treatment of In‐Hospital Cardiac Arrest: A Nationwide Analysis From the United States
Mohamoud, Abdilahi , Abdallah, N. Ben , Ismayl, Mahmoud , Linzer, Mark , Karim, Rehan, Wardhere, Abdirahman , Goldsweig, Andrew M. , Abdallah, Nadhem , Goldsweig, Andrew M , Ismayl, Mahmoud , Johnson, Dawn

Mayo Clinic

Journal of the American Heart Association | November 11, 2024 | Volume: 14 | Issue: 4 | Pages: No page available

10.1161/jaha.124.038683 | PMID 39526496 Get It

Background In‐hospital cardiac arrest (IHCA) is associated with significant morbidity and mortality. The relationships between race and ethnicity and sex on outcomes and treatment patterns among patients with IHCA remain poorly understood. Methods and Results We conducted a retrospective study using the National (Nationwide) Inpatient Sample (NIS) database from 2016 to 2020 to identify adult patients with IHCA and examine the associations between in‐hospital outcomes and race and ethnicity (White, Black, Hispanic) and sex. The primary outcome was in‐hospital mortality. Secondary outcomes included rates of in‐hospital procedures. Multivariable logistic regression analysis was used to adjust for potential confounders. Among 207 770 patients with IHCA, 26.6% had ventricular tachycardia/ventricular fibrillation and 73.4% had pulseless electrical activity/asystole. For ventricular tachycardia/ventricular fibrillation arrest, Black men (adjusted odds ratio [aOR], 1.42 [95% CI, 1.21–1.66]), Black women (aOR, 1.25 [95% CI, 1.05–1.50]), and Hispanic women (aOR, 1.30 [95% CI, 1.01–1.66]) had higher odds of mortality compared with White men (corresponding adjusted risk ratios [aRRs], 1.10 [CI, 1.06–1.14], 1.06 [95% CI, 1.02–1.11], and 1.08 [95% CI, 1.01–1.14], respectively). In the pulseless electrical activity/asystole arrest subgroup, Black men (aOR, 1.25 [95% CI, 1.11–1.39]) and Hispanic men (aOR, 1.22 [95% CI, 1.07–1.40]) had higher odds of mortality (corresponding aRRs, 1.04 [95% CI, 1.02–1.06] and 1.04 [95% CI, 1.01–1.06], respectively). Black patients with IHCA were less likely to receive percutaneous coronary intervention, coronary artery bypass grafting, and mechanical circulatory support compared with White men. Conclusions Significant racial and ethnic and sex disparities exist in outcomes and treatment patterns among patients with IHCA. Targeted efforts and further studies are needed to better understand and address these disparities and improve outcomes.
Renal Effects of Combination Phosphodiesterase V Inhibition and Low-Dose B-Type Natriuretic Peptide in Acute Heart Failure: A Randomized Clinical Trial
Hubers, Scott , Benike, Sherry L., Johnson, Bradley K. , Scott, Christopher G. , Chen, Horng H. , Hubers, Scott A , McKie, Paul M , Scott, Christopher , Chen, Horng , McKie, Paul M.

Mayo Clinic

Circulation: Heart Failure | November 8, 2024 | Volume: 17 | Issue: 12 | Pages: No page available

10.1161/circheartfailure.124.011761 | PMID 39513267 Get It

BACKGROUND: Cardiorenal dysfunction with impaired cyclic GMP (cGMP) response is common in patients presenting with acute heart failure (HF). Type V phosphodiesterase (PDEV) is known to be upregulated in HF and may explain the dysfunction of renal response. The aim of this study was to determine whether B-type natriuretic peptide (BNP) alone or in combination with PDEV inhibition improves renal function and increases urinary sodium and cGMP excretion in acute HF. METHODS: This open-label study included 67 patients hospitalized with acute HF and renal dysfunction. Patients were randomized to standard care, low-dose intravenous BNP (0.005 µg/kg per minute), or combination BNP/PDEV inhibition with sildenafil (25 mg q12 hours) for 48 hours. The coprimary end points were the percent change in estimated glomerular filtration rate and blood urea nitrogen from baseline to 48 hours. RESULTS: Treatment with BNP and BNP/PDEV inhibitor significantly increased plasma cGMP at 24 hours (+25.6% [+9.8%, +84.7%] and +60.8% [+32.3%, +103.8%] for BNP and BNP/PDEV versus −13.5% [−29.1%, +14.2%] with standard care; P =0.001). However, there was no significant change in estimated glomerular filtration rate 0 (−10.8%, +12.7%) for standard care versus 0 (−15.3%, +11.8%) for the BNP group versus –8.8% (−14.3%, +8.3%) for the BNP/PDEV group ( P =0.60) or blood urea nitrogen −1.4% (−10.7%, +12.0%) for standard care versus –5.9% (−14.6%, +9.4%) for the BNP group versus +6.9% (−5.3%, +18.8%) for the BNP/PDEV group ( P =0.38) between groups. Hypotension was more common in the BNP/PDEV inhibitor group. CONCLUSIONS: BNP and combination BNP/PDEV inhibition increased plasma cGMP in patients with acute HF but did not improve renal function or urinary sodium/cGMP excretion. Our study does not support the use of intravenous low-dose BNP with or without PDEV inhibition to enhance renal function in patients admitted with acute HF. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00972569.
Surgical Predictors of Clinical Outcome 6 Years After Revision ACL Reconstruction
Group, The MARS, Wright, Rick W. , Huston, Laura J. , Haas, Amanda K. , Cooper, Daniel E. , Dunn, Warren R. , Lantz, Brett A., Amendola, Annunziato , Annunziata, Christopher C., Arciero, Robert A. , Bach, Bernard R. , Baker, Champ L., Bartolozzi, Arthur R. , Baumgarten, Keith M. , Berg, Jeffrey H., Bernas, Geoffrey A., Brockmeier, Stephen F. , Bush‐Joseph, Charles A., Butler, J. Brad, Carey, James L. , Carpenter, James E. , Cole, Brian J. , Cooper, Jonathan M., Creighton, R. Alexander , Flanigan, David C. , Frederick, Robert W., Ganley, Theodore J. , Gatt, Charles J. , Gecha, Steven R., Hame, Sharon L. , Hannafin, Jo A., Harner, Christopher D. , Harris, Norman Lindsay, Hechtman, Keith S., Hershman, Elliott B., Hoellrich, Rudolf G., Johnson, David C. , Kaeding, Christopher C., Kamath, Ganesh V. , Klootwyk, Thomas E., Levy, Bruce A. , Benjamin, C. , Maiers, G. Peter, Marx, Robert G. , Matava, Matthew J. , Mathien, Gregory M., McCormack, Robert G. , Miller, Bruce S., Nissen, Carl W. , O’Neill, Daniel F., Parker, Richard D., Purnell, Mark L., Ramappa, Arun J. , Rauh, Michael A. , Rettig, Arthur C., Sekiya, Jon K., Shea, Kevin G. , Slauterbeck, James R., Smith, Matthew V. , Svoboda, Steven J. , Taft, Timothy N., Tenuta, Joachim J., Tingstad, Edwin M., Vidal, Armando F. , Viskontas, Darius G., White, Richard A., Wolcott, Michelle L., York, James J. , Group, The MARS, Pennings, Jacquelyn S. , Allen, Christina R. , DeBerardino, Thomas M. , Spindler, Kurt P , Stuart, Michael J. , Brophy, Robert H. , Cox, Charles L. , David, Tal S. , Giffin, J. Robert , Johnson, David C., Johnson, Timothy S. , Jones, Morgan H. , Kaeding, Christopher C. , McAllister, David R. , McCarty, Eric C. , Miller, Bruce S., Owens, Brett D. , Sherman, Orrin H. , Spang, Jeffrey T. , Vidal, Armando F. , Williams, James S. , Wolf, Brian R.

Mayo Clinic

The American Journal of Sports Medicine | November 6, 2024 | Volume: 52 | Issue: 13 | Pages: 3286-3294

10.1177/03635465241288227 | PMID 39503722 Get It

Background: Revision anterior cruciate ligament (ACL) reconstruction has been documented to have inferior outcomes compared with primary ACL reconstruction. The reasons why remain unknown. Purpose: To determine whether surgical factors performed at the time of revision ACL reconstruction can influence a patient’s outcome at 6-year follow-up. Study Design: Cohort study; Level of evidence, 2. Methods: Patients who underwent revision ACL reconstruction were identified and prospectively enrolled between 2006 and 2011. Data collected included baseline patient characteristics, surgical technique and pathology, and a series of validated patient-reported outcome instruments: Knee injury and Osteoarthritis Outcome Score (KOOS), International Knee Documentation Committee (IKDC) subjective form, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), and Marx activity rating score. Patients were followed up for 6 years and asked to complete the identical set of outcome instruments. Regression analysis was used to control for baseline patient characteristics and surgical variables to assess the surgical risk factors for clinical outcomes 6 years after surgery. Results: A total of 1234 patients were enrolled (716 men, 58%; median age, 26 years), and 6-year follow-up was obtained on 79% of patients (980/1234). Using an interference screw for femoral fixation compared with a cross-pin resulted in significantly better outcomes in 6-year IKDC scores (odds ratio [OR], 2.2; 95% CI, 1.2-3.9; P = .008) and KOOS sports/recreation and quality of life subscale scores (OR range, 2.2-2.7; 95% CI, 1.2-4.8; P < .01). Use of an interference screw compared with a cross-pin resulted in a 2.6 times less likely chance of having a subsequent surgery within 6 years. Use of an interference screw for tibial fixation compared with any combination of tibial fixation techniques resulted in significantly improved scores for IKDC (OR, 1.96; 95% CI, 1.3-2.9; P = .001); KOOS pain, activities of daily living, and sports/recreation subscales (OR range, 1.5-1.6; 95% CI, 1.0-2.4; P < .05); and WOMAC pain and activities of daily living subscales (OR range, 1.5-1.8; 95% CI, 1.0-2.7; P < .05). Use of a transtibial surgical approach compared with an anteromedial portal approach resulted in significantly improved KOOS pain and quality of life subscale scores at 6 years (OR, 1.5; 95% CI, 1.02-2.2; P≤ .04). Conclusion: There are surgical variables at the time of ACL revision that can modify clinical outcomes at 6 years. Opting for a transtibial surgical approach and choosing an interference screw for femoral and tibial fixation improved patients’ odds of having a significantly better 6-year clinical outcome in this cohort.
Risk of malignancy in thyroid nodules with increased 11C-Choline uptake detected incidentally on PET/CT: A diagnostic accuracy study
Lima, Livia Maria Frota, Bogsrud, Trond Velde , Gharib, Hossein, Ryder, Mabel , Durski, Jolanta M. , Frota Lima, Livia Maria, Johnson, Geoffrey , Durski, Jolanta, Ryder, Mabel , Johnson, Geoffrey B.

Mayo Clinic

Medicine | November 6, 2024 | Volume: 103 | Issue: 36 | Pages: e39602

10.1097/md.0000000000039602 | PMID 39252246 Get It

Purpose: The purpose was to evaluate the pathological nature of focal thyroid uptake seen in 11C-Choline PET/CT performed for prostate cancer. Material and methods: The study was IRB-approved. All 11C-Choline PET/CT exam reports for studies performed between January 01, 2018, and July 30, 2021, in male patients with prostate cancer in our institution were retrospectively reviewed. Exams with “focal thyroid uptake” on their final report were selected. Patients with surgery or ablation in the thyroid prior to the PET/CT, proven parathyroid adenomas or absent thyroid ultrasound were excluded. Repeated PET/CT exams of same patient were excluded. PET images were analyzed visually and semi-quantitatively by measuring the maximum standardized uptake value (SUVmax) of the focal thyroid uptake. Available thyroid ultrasound images, cytology and pathology reports were reviewed. Statistical analyses were performed. Results: Out of 10,047 sequential 11C-Choline PET/CT studies, 318 reports included “focal thyroid uptake.” About 128 of these studies were repeat exams and were excluded. Additional 87 patients were excluded, because the uptake was determined to be adjacent, rather than confined to the thyroid gland. Out of the remaining 103 patients, 74 patients had focal thyroid uptake and concurrent thyroid sonographic evaluation. Out of the 74 focal uptakes evaluated with ultrasound, 21 were presumed benign thyroid nodules based on the ultrasound and 53 had further evaluation with biopsy. Sixty three nodules were benign (21 presumed benign on ultrasound and 42 cytology or surgical pathology-proven), 9 nodules were malignant and 2 remained indeterminate. There was no significant difference between the SUVs of the benign and malignant groups (P > .3). Conclusion: In this retrospective study of patients with prostate cancer who underwent 11C-Choline PET/CT, we identified a group of patients who underwent thyroid ultrasound for incidental finding of focal 11C-Choline thyroid uptake. Incidence of malignancy in this group was 12%. Therefore, further investigation with ultrasound and possibly ultrasound-guided biopsy may be warranted when a choline avid thyroid nodule is found incidentally on choline PET.
Vestibular Schwannoma Koos Grade I International Study of Active Surveillance Versus Stereotactic Radiosurgery: The VISAS-K1 Study
Bin-Alamer, Othman , Peker, Selçuk , Samancı, Yavuz , Pelcher, Isabelle , Begley, Sabrina , Goenka, Anuj , Schulder, Michael , Tourigny, Jean-Nicolas, Hamel, Andréanne, Briggs, Robert G. , Yu, Cheng , Zada, Gabriel , Giannotta, Steven L., Palque, Sarai, Kumar, Narendra , Rogowski, Brandon, Shepard, Matthew J., Warnick, Ronald E. , Dayawansa, Sam , Vasconcellos, Fernando De Nigris , Bernstein, Kenneth , Sheehan, Jason P. , Johnson, Bryan A, Sheehan, Jason , Bin-Alamer, Othman , Abou‐Al‐Shaar, Hussam , Mathieu, David , Giannotta, Steven L. , Speckter, Herwin , Tripathi, Manjul , Kumar, Saurabh , Kaur, Rupinder , Johnson, Bryan A., Trifiletti, Daniel M. , Mashiach, Elad , Schnurman, Zane , Alzate, Juan Diego , Kondziolka, Douglas

Mayo Clinic

Neurosurgery | November 6, 2024 | Volume: 96 | Issue: 1 | Pages: 41-49

10.1227/neu.0000000000003215 | PMID 39503441 Get It

BACKGROUND AND OBJECTIVE: This investigation evaluates the safety and efficacy of stereotactic radiosurgery (SRS) vs observation for Koos grade I vestibular schwannomas (VS). METHODS: In a multicenter study, we retrospectively analyzed data of patients with Koos grade I VS who underwent SRS (SRS group) or were observed (observation group). Propensity score matching was used to equilibrate demographics, tumor size, and audiometric data across groups. The outcome analyzed included tumor control, preservation of serviceable hearing, and neurological function. RESULTS: The study matched 142 patients, providing a median follow-up period of 36 months. SRS significantly enhanced tumor control compared with observation, with a 100% control rate at both 5- and 8-year marks in the SRS group vs 48.6% and 29.5% in the observation group at the same time intervals, respectively ( P < .001). Preservation of serviceable hearing outcomes between groups showed no significant difference at 5 and 8 years, ensuring a comparable quality of auditory function (SRS 70.1% vs observation 53.4% at 5 years; P = .33). Furthermore, SRS was associated with a reduced likelihood of tinnitus (odds ratio [OR] = 0.46, P = .04), vestibular dysfunction (OR = 0.17, P = .002), and overall cranial nerve dysfunction (OR = 0.49, P = .03) at last follow-up. CONCLUSION: SRS management of patients with Koos grade I VS was associated with superior tumor control and reduced odds for cranial nerve dysfunction, while not compromising hearing preservation compared with observation. These findings support the safety and efficacy of SRS as a primary care approach for this patient population.
Vestibular Schwannoma Koos Grade II International Study of Active Surveillance Versus Stereotactic Radiosurgery: The VISAS-K2 Study
Bin-Alamer, Othman , Peker, Selçuk , Samanci, Yavuz, Pelcher, Isabelle , Begley, Sabrina , Goenka, Anuj , Schulder, Michael , Tourigny, Jean-Nicolas, Hamel, Andréanne, Briggs, Robert G. , Yu, Cheng , Zada, Gabriel , Giannotta, Steven L., Palque, Sarai, Kumar, Narendra , Rogowski, Brandon, Shepard, Matthew J., Warnick, Ronald E. , Dayawansa, Sam , Vasconcellos, Fernando De Nigris , Bernstein, Kenneth , Sheehan, Jason P. , Samancı, Yavuz , Johnson, Bryan A, Sheehan, Jason , Bin-Alamer, Othman , Abou‐Al‐Shaar, Hussam , Mathieu, David , Giannotta, Steven L. , Speckter, Herwin , Tripathi, Manjul , Kumar, Saurabh , Kaur, Rupinder , Johnson, Bryan A., Trifiletti, Daniel M. , Mashiach, Elad , Schnurman, Zane , Alzate, Juan Diego , Kondziolka, Douglas

Mayo Clinic

Neurosurgery | November 6, 2024 | Volume: 96 | Issue: 1 | Pages: 50-58

10.1227/neu.0000000000003216 | PMID 39503444 Get It

BACKGROUND AND OBJECTIVES: This study assessed the efficacy and safety of stereotactic radiosurgery (SRS) in comparison with watchful waiting for managing Koos grade II vestibular schwannomas (VS). METHODS: A retrospective, multicentric analysis was conducted, focusing on patients with Koos grade II VS who either received SRS (SRS group) or were observed (observation group). To ensure comparability between groups, propensity score matching was used, including factors such as demographic characteristics, tumor dimensions, and hearing assessments. The primary end points examined were tumor control, maintenance of serviceable hearing, and neurological outcomes. RESULTS: A total of 92 patients were equally matched across both cohorts, with a median follow-up of 37 months for the SRS group and 27.5 months for those observed. The SRS cohort exhibited superior tumor control over observation across 3, 5, and 8 years, achieving a 100% control rate vs 47.9%, 40.1%, and 34.3% for the observation group at these time intervals, respectively ( P < .001). Serviceable hearing preservation rates were comparable between the 2 groups throughout 3, 5, and 7 years (72.9% for SRS vs 65.4% for observation at 3 years; P = .86). Moreover, SRS management correlated with a lower incidence of vestibular symptoms (odds ratio = 0.11, P = .002), with no significant disparity in the deterioration of cranial nerve (CN) V or CN VII functions. Notably, the likelihood of experiencing any CN impairment was significantly diminished in the SRS cohort (odds ratio = 0.47, P = .04). CONCLUSION: For patients with Koos grade II VS, SRS offers superior tumor control rate and a lower risk of CN dysfunction without sacrificing hearing preservation.
Quantifying Mast Cell and Eosinophil Cellular Density in Skin Biopsy Tissue From Adults With Maculopapular Cutaneous Mastocytosis as Compared With Urticaria and Normal Skin: A Retrospective Histopathologic Study
King, Anne L. , Agrawal, Shruti , Wieland, Carilyn N. , Lehman, Julia S. , Johnson, Emma F. , Lehman, Julia S , King, Anne L., Montagnon, Carmen M. , Todd, Austin W.

Mayo Clinic

The American Journal of Dermatopathology | November 5, 2024 | Volume: 47 | Issue: 2 | Pages: 105-109

10.1097/dad.0000000000002878 | PMID 39498907 Get It

Background: Maculopapular cutaneous mastocytosis (MPCM) is a rare disorder characterized by a pathologic accumulation of mast cells in the skin, which may or may not be accompanied by systemic mastocytosis. Diagnosis of MPCM on skin biopsy can be challenging because the findings may be subtle. Although mast cell density in MPCM has been reported, data informing a proposed cutoff for diagnosis and diagnostic criteria are limited. Methods: We identified adult patients diagnosed with MPCM and urticarial tissue reaction/chronic urticaria on skin biopsy and compared the mast cell and eosinophil counts per 1 mm2 in 10 cases each of MPCM, chronic urticaria, and normal skin from routine biopsies. All slides were stained with CD117, and CD117-positive mast cells were counted per 1 mm2 using digital microscopy. Eosinophils were counted on hematoxylin and eosin-stained slides per 1 mm2 using digital microscopy. Results: The median number of mast cells per 1 mm2 was significantly higher in MPCM than in cases of urticaria and normal skin/control tissue (177.3 vs. 26.8 vs. 47.8 mast cell per mm2, respectively; P ≤ 0.001). The calculated “cut point” for mastocytosis versus chronic urticaria and normal skin was 66 mast cells per 1 mm2, whereas the value for controls versus urticaria was 37 mast cells per 1 mm2. Eosinophils had similar density in MPCM and urticaria, and their presence was significant in the differentiation of MPCM and urticaria from normal tissue. Conclusions: This study adds to the literature by providing objective mast cell density data to distinguish challenging cases of cutaneous mastocytosis from urticarial reactions and normal skin. Future studies could explore the development of computer-aided estimations of cellular density with more extensive comparison with other inflammatory conditions to translate our findings more readily into clinical practice.
The economic impact associated with stent retriever selection for the treatment of acute ischemic stroke: a cost–effectiveness analysis of MASTRO I data from a Chinese healthcare system perspective
Zaidat, Osama O. , Yang, Xinguang , Brinjikji, Waleed , Kottenmeier, Emilie , Maheswaran, Hendramoorthy , Galvain, Thibaut , Brouwer, Patrick A. , Mirza, Mahmood , Andersson, Tommy , Andersson, Tommy , Brouwer, Patrick , Kottenmeier, Emilie

Mayo Clinic

Journal of Comparative Effectiveness Research | November 5, 2024 | Volume: 13 | Issue: 11 | Pages: No page available

10.57264/cer-2024-0160 | PMID 39498634 Get It

Aim: The aim of this analysis was to assess the cost–effectiveness of the EmboTrap ® Revascularization Device compared with the Solitaire™ Revascularization Device and Trevo ® Retriever for the treatment of acute ischemic stroke (AIS) from the perspective of the Chinese healthcare system. Methods: According to MASTRO I, a recent living systematic literature review and meta-analysis, mechanical thrombectomy (MT) with EmboTrap in the treatment of AIS resulted in better functional outcomes compared with the use of Solitaire or Trevo. Based on the proportion of patients that achieved 90-day modified Rankin Scale (mRS) scores of 0–2, 3–5 and 6 reported in MASTRO I, a combined 90-day short-term decision tree and Markov model with a 10-year time horizon was used to compare the cost–effectiveness of the three devices. The primary outcome was the incremental cost–effectiveness ratio (ICER), representing the incremental cost (in 2022 Chinese Yuan [CNY]) per incremental quality-adjusted life-year (QALY). The ICERs were compared against willingness-to-pay (WTP) thresholds of 1, 1.5 and 3-times the 2022 national gross domestic product (GDP) per capita in China. Results: Treatment with EmboTrap resulted in total QALYs of 3.28 and total costs of 110,058 CNY per patient. Treatment with Trevo resulted in total QALYs of 3.05 and total costs of 116,941 CNY per patient. Treatment with Solitaire resulted in total QALYs of 2.81 and total costs of 99,090 CNY per patient. Trevo was dominated by EmboTrap as it was a more costly and less effective intervention. As such, Trevo was not cost-effective at any WTP threshold. Compared with Solitaire, EmboTrap was more effective and more costly, with an ICER of 23,615 CNY per QALY. This result suggests that EmboTrap is cost-effective when compared with Solitaire since the ICER was lower than all WTP thresholds assessed. Conclusion: EmboTrap dominated Trevo and is cost-effective for the treatment of patients with AIS compared with Solitaire when assessed from the perspective of the Chinese healthcare system and based on the device-level meta-analysis MASTRO I. Selecting a stent retriever (SR) that optimizes 90-day mRS score is an important consideration from both a clinical and healthcare payer perspective in China as it is associated with reduced long-term costs and increased quality of life.
Detection of Right and Left Ventricular Dysfunction in Pediatric Patients Using Artificial Intelligence–Enabled ECGs
Anjewierden, Scott , O’Sullivan, Donnchadh , Mangold, Kathryn, Greason, Grace , Attia, Zachi I. , López-Jiménez, Francisco , Friedman, Paul A. , Asirvatham, Samuel J. , Anderson, Jason H. , Eidem, Benjamin W., Johnson, Jonathan N. , Prakash, Shisheer Havangi, Madhavan, Malini , Mangold, Kathryn E , Attia, Zachi I , Anderson, Jason , Havangi Prakash, Shisheer, Niaz, Talha , Madhavan, Malini , Asirvatham, Samuel J , Lopez-Jimenez, Francisco , Niaz, Talha

Mayo Clinic

Journal of the American Heart Association | November 4, 2024 | Volume: 13 | Issue: 21 | Pages: No page available

10.1161/jaha.124.035201 | PMID 39494568 Get It

Background Early detection of left and right ventricular systolic dysfunction (LVSD and RVSD respectively) in children can lead to intervention to reduce morbidity and death. Existing artificial intelligence algorithms can identify LVSD and RVSD in adults using a 12‐lead ECG; however, its efficacy in children is uncertain. We aimed to develop novel artificial intelligence–enabled ECG algorithms for LVSD and RVSD detection in pediatric patients. Methods and Results We identified 10 142 unique pediatric patients (age≤18) with a 10‐second, 12‐lead surface ECG within 14 days of a transthoracic echocardiogram, performed between 2002 and 2022. LVSD was defined quantitatively by left ventricular ejection fraction (LVEF). RVSD was defined semiquantitatively. Novel pediatric models for LVEF ≤35% and LVEF <50% achieved excellent test areas under the curve of 0.93 (95% CI, 0.89–0.98) and 0.88 (95% CI, 0.83–0.94) respectively. The model to detect LVEF <50% had a sensitivity of 0.85, specificity of 0.80, positive predictive value of 0.095, and negative predictive value of 0.995. In comparison, the previously validated adult data‐derived model for LVEF <35% achieved an area under the curve of 0.87 (95% CI, 0.84–0.90) for LVEF ≤35% in children. A novel pediatric model for any RVSD detection reached a test area under the curve of 0.90 (0.87–0.94). Conclusions An artificial intelligence–enabled ECG demonstrates accurate detection of both LVSD and RVSD in pediatric patients. While adult‐trained models offer good performance, improvements are seen when training pediatric‐specific models.
Human Stem Cell–Derived Cardiomyocytes Integrate Into the Heart of Monkeys With Right Ventricular Pressure Overload
Scholz, Jodi A. , Secreto, Frank J., Wobig, Joan, Kurian, Joe R, Hagen, Clint , Zinnen, Alexandra D. , Vu, Don, Johnson, Steven J., Cetta, Frank , Qureshi, M. Yasir , Reams, Rachel Y., Cannon, Bryan C. , Heyer, Christina M., Chang, Min‐Hwang , Fadra, Numrah, Coonen, Jennifer , Simmons, Heather A. , Mejía, Andrés , Hayes, Jennifer M. , Basu, Puja , Capuano, Saverio , Bondarenko, Viktoriya, Metzger, Jeanette M. , Nelson, Timothy J., Scholz, Jodi, Qureshi, Muhammad Y , Cannon, Bryan, Emborg, Marina E , Vu, Don, Johnson, Steven J., Nelson, Timothy J.

Mayo Clinic

Cell Transplantation | November 2, 2024 | Volume: 33 | Issue: No issue available | Pages: No page available

10.1177/09636897241290367 | PMID 39487759 Get It

Cardiac ventricular pressure overload affects patients with congenital heart defects and can cause cardiac insufficiency. Grafts of stem cell–derived cardiomyocytes are proposed as a complementary treatment to surgical repair of the cardiac defect, aiming to support ventricular function. Here, we report successful engraftment of human induced pluripotent stem cell–derived cardiac lineage cells into the heart of immunosuppressed rhesus macaques with a novel surgical model of right ventricular pressure overload. The human troponin+ grafts were detected in low-dose (2 × 10 6 cells/kg) and high-dose (10 × 10 6 cells/kg) treatment groups up to 12 weeks post-injection. Transplanted cells integrated and progressively matched the organization of the surrounding host myocardium. Ventricular tachycardia occurred in five out of 16 animals receiving cells, with episodes of incessant tachycardia observed in two animals; ventricular tachycardia events resolved within 19 days. Our results demonstrate that grafted cardiomyocytes mature and integrate into the myocardium of nonhuman primates modeling right ventricular pressure overload.